31.05.2015 17:22:10
|
Pharmacyclics Presents Interim Results From Ongoing Phase Ib/II PCYC-1129 Study
(RTTNews) - Pharmacyclics LLC (PCYC) reported interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease, or cGVHD, who were either refractory to steroid treatment or were steroid-dependent. The company said, in a preliminary analysis, data show all five evaluable patients who had received at least three months of ibrutinib achieved a partial response, and two patients who were evaluable at six months maintained a partial response.
The ongoing Phase Ib/II study evaluated the safety and efficacy of ibrutinib for the treatment of patients with steroid-dependent or refractory cGVHD. The Phase Ib portion of the study was open-label and designed to determine the recommended Phase II dose of ibrutinib, starting at 420 mg. As a result of the preliminary evaluation of the available data, researchers determined the Phase II dose of ibrutinib to be 420 mg. The Phase II study is currently ongoing.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pharmacyclics Incmehr Nachrichten
Keine Nachrichten verfügbar. |